Medtronic PLC (MDT) reported its financial results for the fourth quarter of fiscal 2026, revealing earnings per share (EPS) of $1.55, slightly below the Wall Street consensus of $1.56. Revenue for the quarter reached $9.8 billion, surpassing the expected $9.7 billion.
The results indicate a performance that met analyst estimates, reflecting stability in the company’s operations. Medtronic, a leader in medical technology, engages in the development and distribution of device-based medical therapies. Its product categories encompass a wide range of medical fields, including cardiovascular, neurological, and surgical technologies.
The company will host an earnings conference call to discuss these results further and provide additional insights into its business performance. Investors are encouraged to review the full earnings release and listen to management commentary for a comprehensive understanding of the quarter's performance and future outlook.
As of June 2, 2026, Medtronic holds a market capitalization of $95.1 billion, with a trailing P/E ratio of 20.60 and a dividend yield of 383.9%. Looking ahead, the company is set to report its next earnings on August 17, 2026, with EPS and revenue estimates of $1.40 and $9.4 billion, respectively.